Found 180 articles
Exscientia (Nasdaq: EXAI) will report financial results for the fourth quarter and full year ended December 31, 2021, on Wednesday, March 23, 2022 after U.S. market close.
Rallybio Corporation today reported financial results for the fourth quarter and full year ended December 31, 2021 and provided an update on recent corporate developments.
The global AI in pharmaceutical market size is expected to be worth around USD 9.24 billion by 2030 from valued at USD 905.91 million in 2021 with a CAGR of 29.4% from 2021 to 2030.
Exscientia and University of Oxford Launch “Xcellomics” Program to Expedite Early-Stage Academic Research and Translate Novel Biology Into Future Drug Discovery
Exscientia and the University of Oxford Target Discovery Institute announced the formation of Xcellomics – a program designed to source cellular functional assays from the global academic community to develop novel screens and identify targets and therapeutic candidates for unmet medical needs.
Exscientia to Highlight Precision Medicine Platform and Pipeline Data at the American Association of Cancer Research Annual Meeting 2022
Exscientia (Nasdaq: EXAI) today announced the acceptance of three abstracts for poster presentation at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2022, being held April 8-13, 2022, at the Ernest N. Morial Convention Center in New Orleans, LA.
Exscientia announced that Andrew Hopkins, DPhil., Exscientia’s founder and CEO and Ben Taylor, CFO & Chief Strategy Officer, will participate in fireside chats at the following investor conferences in March:
Intelligent Drug Discovery Market to Reach USD 3,711.8 Million by 2027 Growing at a CAGR of 39.4%, says Emergen Research
The global Intelligent Drug Discovery Market is forecasted to be worth USD 3,711.8 Million by 2027, according to a current analysis by Emergen Research.
1/21/2022Biopharma and life sciences companies made numerous appointments this week to boards and executive teams. These Movers & Shakers will position the companies for future growth.
Professor Charlotte Deane, Ph.D., of the University of Oxford, has joined Exscientia as Chief Scientist of Biologics AI.
Since Rallybio launched in 2018, the company has been laser-focused on the development of "transformative therapeutics" for patients suffering from rare and ultra-rare diseases.
Intelligent Drug Discovery Market Size to Reach USD 5,174.24 Million in 2028 Growing at a CAGR of 39.4%, according to Emergen Research
According to Emergen Research, the global intelligent drug discovery market size was USD 360.90 million in 2020 and is expected to reach USD 5,174.24 million in 2028 and register a revenue CAGR of 39.4% during the forecast period, 2021-2028.
Sanofi has signed a collaboration deal with Exscientia to leverage the latter's artificial intelligence platform and develop up to 15 oncology and immunology therapies.
Exscientia and Sanofi establish strategic research collaboration to develop AI-driven pipeline of precision-engineered medicines
Sanofi and Exscientia announced a groundbreaking research collaboration and license agreement to develop up to 15 novel small molecule candidates across oncology and immunology, leveraging Exscientia’s end-to-end AI-driven platform utilizing actual patient samples.
Rallybio Corporation today provided an update on recent accomplishments and announced expected upcoming milestones.
AI in Drug Discovery Market to Expand by 36.1% CAGR as Popularity of Mindful AI Offers Breakthrough Opportunities, Notes TMR
According to the report, the global AI in drug discovery market was valued at US$ 0.35 Bn in 2020 and is projected to expand at a CAGR of 36.1% from 2021 to 2031.
Exscientia (Nasdaq: EXAI) today announced they will participate in a fireside chat at the Evercore ISI 4th Annual HealthCONx Virtual Conference on Thursday, December 2, 2021 at 10:30 a.m. ET (3:30 p.m. GMT).
Evotec SE announced the financial results and corporate updates for the first nine months 2021.
Exscientia will report financial results for the third quarter ended September 30, 2021, on Wednesday, November 17, 2021 after U.S. market close.
Isomorphic Laboratories has expressed plans to foray into drug discovery and development by tapping into the technology of its sister company DeepMind.
10/18/2021It was yet another busy week for clinical trial announcements. Take a look.